Lucentis, developed by Genentech, is a medication used to treat conditions affecting the eye, specifically neovascular age-related macular degeneration (wet AMD), diabetic macular edema (DME), and other retinal diseases [1].
What is Lucentis used to treat?
Lucentis is prescribed for the treatment of wet age-related macular degeneration (AMD), a leading cause of vision loss in older adults. It is also indicated for diabetic macular edema (DME), a complication of diabetes that affects vision, and for visual impairment due to other retinal vascular diseases [1].
How does Lucentis work?
Lucentis, whose active ingredient is ranibizumab, is an antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A) [1]. VEGF-A plays a critical role in the development of choroidal neovascularization (CNV), which is implicated in the pathogenesis of wet AMD and DME. By blocking VEGF-A, Lucentis helps to reduce the leakage and growth of abnormal blood vessels in the retina, thereby aiming to preserve or improve vision [1].
When does the patent for Lucentis expire?
The patent landscape for Lucentis is complex, involving multiple patents that cover various aspects of the drug. Information regarding specific patent expiration dates can be found on DrugPatentWatch.com [2].
Who makes Lucentis?
Lucentis was developed by Genentech, a member of the Roche Group [1].
What are the side effects of Lucentis?
Common side effects of Lucentis injections may include eye pain, increased intraocular pressure, and inflammation within the eye. More serious risks, though rare, can include endophthalmitis (a severe eye infection) and retinal detachment [1].
Are there alternatives to Lucentis?
Yes, there are alternative treatments for wet AMD and DME. These include other anti-VEGF therapies such as Eylea (aflibercept) and Beovu (brolucizumab), as well as other treatment modalities. The choice of treatment depends on the specific condition, patient factors, and physician recommendation [3].
What is the difference between Lucentis and Eylea?
Both Lucentis (ranibizumab) and Eylea (aflibercept) are anti-VEGF medications used to treat wet AMD and DME. They work by inhibiting VEGF, but they differ in their molecular structure and binding affinity to VEGF. Clinical studies have compared their efficacy and safety, with results suggesting comparable outcomes for many patients, though differences in dosing frequency and administration may exist [3].
What is the cost of Lucentis?
The cost of Lucentis can vary significantly based on insurance coverage, geographic location, and pharmacy. It is a prescription medication administered via intravitreal injection, and treatment regimens typically involve multiple injections over time. Patients often incur co-pays for the drug and administration.
What is the regulatory status of Lucentis?
Lucentis has received approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) for its indicated uses [1].
---
Sources:
[1] https://www.gene.com/medicines/lucentis
[2] https://drugpatentwatch.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861921/